These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 23085878)
21. A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Kubota K; Sakai H; Yamamoto N; Kunitoh H; Nakagawa K; Takeda K; Ichinose Y; Saijo N; Ariyoshi Y; Fukuoka M J Thorac Oncol; 2010 May; 5(5):702-6. PubMed ID: 20150827 [TBL] [Abstract][Full Text] [Related]
22. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Sause W; Kolesar P; Taylor S IV; Johnson D; Livingston R; Komaki R; Emami B; Curran W; Byhardt R; Dar AR; Turrisi A Chest; 2000 Feb; 117(2):358-64. PubMed ID: 10669675 [TBL] [Abstract][Full Text] [Related]
23. Evidence-based role of bevacizumab in non-small cell lung cancer. Vokes EE; Salgia R; Karrison TG Ann Oncol; 2013 Jan; 24(1):6-9. PubMed ID: 23251009 [No Abstract] [Full Text] [Related]
24. UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma: a multiinstitutional phase II trial. For the Japan UFT Lung Cancer Study Group. Ichinose Y; Yosimori K; Yoneda S; Kuba M; Kudoh S; Niitani H Cancer; 2000 Jan; 88(2):318-23. PubMed ID: 10640963 [TBL] [Abstract][Full Text] [Related]
25. Medical oncology: Chemoradiotherapy for NSCLC-does a 'standard' exist? Chen AM; Lara PN Nat Rev Clin Oncol; 2011 Jan; 8(1):5-6. PubMed ID: 21102530 [No Abstract] [Full Text] [Related]
26. A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development. Roviello G; Nobili S; Mini E J Chemother; 2019 Oct; 31(6):295-296. PubMed ID: 31432747 [No Abstract] [Full Text] [Related]
27. [The changed role of chemotherapy in the treatment of stage III non-small-cell lung carcinoma]. Belderbos JS; Bartelink H; Boersma LJ; Aleman BM Ned Tijdschr Geneeskd; 1997 Jul; 141(30):1498-9. PubMed ID: 9542887 [No Abstract] [Full Text] [Related]
28. 2005 highlights from: 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 2005. Gibson AD; Stewart J; Reddy GK; Gibson TB Clin Lung Cancer; 2005 Jul; 7(1):11-6. PubMed ID: 16098238 [No Abstract] [Full Text] [Related]
29. [Combination therapy with S-1 plus docetaxel (DOC) for previously treated patients with non-small cell lung cancer]. Atagi S Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():197-201. PubMed ID: 16898002 [TBL] [Abstract][Full Text] [Related]
30. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N; Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337 [TBL] [Abstract][Full Text] [Related]
31. Phase II study of high dose ifosfamide plus mesna in inoperable non small cell lung carcinoma. Pastran Z; le Chevalier T; Baldeyrou P; Spielmann M; Arriagada R; Droz JP; Rouesse J Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1073-4. PubMed ID: 2842161 [No Abstract] [Full Text] [Related]
32. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110). Nishino K; Imamura F; Kumagai T; Katakami N; Hata A; Okuda C; Urata Y; Hattori Y; Tachihara M; Yokota S; Nishimura T; Kaneda T; Satouchi M; Morita S; Negoro S Lung Cancer; 2015 Aug; 89(2):146-53. PubMed ID: 26093793 [TBL] [Abstract][Full Text] [Related]
33. A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019). Belvedere O; Follador A; Rossetto C; Merlo V; Defferrari C; Sibau AM; Aita M; Dal Bello MG; Meduri S; Gaiardo M; Fasola G; Grossi F Eur J Cancer; 2011 Jul; 47(11):1653-9. PubMed ID: 21514147 [TBL] [Abstract][Full Text] [Related]
34. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216 [TBL] [Abstract][Full Text] [Related]
35. Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation. Murakami S; Oshita F; Sugiura M; Kondo T; Saito H; Yamada K Cancer Chemother Pharmacol; 2013 Mar; 71(3):705-11. PubMed ID: 23328865 [TBL] [Abstract][Full Text] [Related]